Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC

Gilead Sciences (NASDAQ:GILD) had its price objective raised by research analysts at HSBC from $110.00 to $133.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. HSBC’s price objective indicates a potential upside of 11.81% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Wells Fargo & Company boosted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. BMO Capital Markets set a $135.00 target price on shares of Gilead Sciences in a research report on Tuesday, November 25th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $130.96.

Gilead Sciences Stock Down 1.8%

Shares of NASDAQ:GILD opened at $118.96 on Wednesday. The business’s 50 day moving average is $121.28 and its 200 day moving average is $115.53. Gilead Sciences has a 12-month low of $88.57 and a 12-month high of $128.70. The stock has a market cap of $147.59 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.67 and a beta of 0.32. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The business’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 135,757 shares of company stock valued at $16,616,127. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after buying an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares in the last quarter. Norges Bank purchased a new position in Gilead Sciences during the second quarter valued at $2,150,268,000. Invesco Ltd. increased its position in Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after buying an additional 11,156,382 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.